Tags : Improvement

Clinical Trials

Sanofi Reports Results of Dupixent (dupilumab) in P-III LIBERTY ASTHMA

Shots: The P-III LIBERTY ASTHMA VOYAGE study involves assessing of Dupixent (SC, 100/200mg, q2w ) + SOC maintenance therapy of medium-dose ICS with a second controller medication/ high-dose ICS with/out second controller medication vs PBO in 408 children 6 to <12 years old with uncontrolled moderate-severe asthma Results: Patients with baseline blood EOS ≥300 cells/μl […]Read More